Compare TNK & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNK | IRON |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2007 | 2020 |
| Metric | TNK | IRON |
|---|---|---|
| Price | $76.70 | $66.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $80.00 | ★ $103.18 |
| AVG Volume (30 Days) | 343.3K | ★ 390.3K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $283.52 |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.05 | $40.00 |
| 52 Week High | $83.99 | $99.50 |
| Indicator | TNK | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 43.70 |
| Support Level | $71.94 | $64.99 |
| Resistance Level | $80.97 | $71.53 |
| Average True Range (ATR) | 2.93 | 3.20 |
| MACD | -0.60 | -0.26 |
| Stochastic Oscillator | 16.73 | 11.24 |
Teekay Tankers Ltd is a provider of marine services to the international oil and natural gas industries and an operator of medium-sized oil tankers. The company operates in two segments: Tankers, which consists of the operation of all of the company's tankers (including the operations from those tankers employed on full service lightering contracts), and the company's U.S. based ship-to-ship support service operations (including its lightering support services provided as part of full service lightering operations); and Marine Services, which consists of operational and maintenance marine services provided to the Australian government, Australian energy companies and other third parties. The company generates the majority of its revenue from the Tankers segment.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.